Q-omics provides the consensus-scored MUC20-OT1 profile across patient tissues and cancer cell-line models. MUC20-OT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MUC20-OT1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, MUC20-OT1 RNA expression shows 18,910 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where MUC20-OT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC20-OT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC20-OT1 survival associations across molecular data types. MUC20-OT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC20-OT1 RNA expression–survival associations across cancer types. High MUC20-OT1 expression shows unfavorable associations in ACC, LIHC and UCEC, but favorable associations in HNSC, BLCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for MUC20-OT1 RNA expression.
This table summarizes MUC20-OT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MUC20-OT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC20-OT1 shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, KIRC, CHOL and KICH. The LIHC box plot shows higher MUC20-OT1 RNA expression in tumor versus normal tissue (log2 FC = +0.592, t-test p < 0.001).
This table shows molecular features associated with MUC20-OT1 in patient tissues and cancer cell lines. In patient samples, MUC20-OT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
